Building on years of experience in large pharma and biotechnology companies our bioscience team offers capabilities specialising in bioassay development, pharmacological profiling and compound screening.
Significant experience of different target classes and the use of cutting edge technologies ensure client projects are delivered to time and budget.
Wide range of technologies
Our team has worked in pre-clinical discovery, designing and developing low, medium and high throughput assays in both cellular and non-cellular assay formats.
Therefore, we have experience of a wide range of technologies designed to prosecute these activities in a scalable manner whilst bringing to bear technological developments that have the ability to probe ever further into the molecular interactions from which the drugs of the future may be identified.
Whatever your therapeutic area or target class we are able to apply our expertise to your project.
We work across the drug discovery pipeline, from target identification, validation and hit to lead, through to lead identification and optimisation.
At Charnwood Molecular , we have significant experience of different target classes and use cutting edge technologies to deliver client projects in a timely, efficient and cost-effective manner.
We can offer standalone biology-based project support through to a fully integrated approach to drug discovery and development, incorporating our services in medicinal and process research chemistry.
Our leadership has decades of large pharma experience in drug discovery gained in companies including Hoffmann La Roche, Smith Kline Beecham, GlaxoWellcome, AstraZeneca, ICI and UCB.
Find out more about our scientific team.
Bioscience capabilities and technologies
- High throughput screening
- Cell based screening
- Phenotypic screening
- Cell culture services
- Biochemical screening
- Instrument & reagent validation
- Liquid handling